Abstract
SEROTONIN (5-hydroxytryptamine, 5-HT) is a monoaminergic neurotransmitter that is believed to modulate numerous sensory, motor and behavioural processes in the mammalian nervous system1-3. These diverse responses are elicited through the activation of a large family of receptor subtypes4. The complexity of this signalling system and the paucity of selective drugs have made it difficult to define specific roles for 5-HT receptor subtypes, or to determine how serotonergic drugs modulate mood and behav-iour. To address these issues, we have generated mutant mice lacking functional 5-HT2C receptors (previously termed 5-HT1C), prominent G-protein-coupled receptors that are widely expressed throughout the brain and spinal cord and which have been proposed to mediate numerous central nervous system (CNS) actions of serotonin3,5-8. Here we show that 5-HT2Creceptor-deficient mice are overweight as a result of abnormal control of feeding behaviour, establishing a role for this receptor in the serotonergic control of appetite. Mutant animals are also prone to spontaneous death from seizures, suggesting that 5-HT2C receptors mediate tonic inhi-bition of neuronal network excitability.
This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Human loss-of-function variants in the serotonin 2C receptor associated with obesity and maladaptive behavior
Nature Medicine Open Access 19 December 2022
-
Cognitive genomics of learning delay and low level of social performance monitoring in macaque
Scientific Reports Open Access 03 October 2022
-
Serotonin 5-HT2C receptor knockout in mice attenuates fear responses in contextual or cued but not compound context-cue fear conditioning
Translational Psychiatry Open Access 11 February 2022
Access options
Subscribe to this journal
Receive 51 print issues and online access
$199.00 per year
only $3.90 per issue
Rent or buy this article
Get just this article for as long as you need it
$39.95
Prices may be subject to local taxes which are calculated during checkout
References
Jacobs, B. L. in Hallucinogens: Neurochemical, Behavioral, and Clinical Perspectives (ed. Jacobs, B. L.) 183–202 (Raven, New York, 1984).
Sleight, A. J., Pierce, P. A., Schmidt, A. W., Hekmatpanah, C. R. & Peroutka, S. J. in Serotonin Receptor Subtypes: Basic and Clinical Aspects (ed. Peroutka, S. J.) 211–227 (Wiley-Liss, New York, 1991).
Wilkinson, L. O. & Dourish, C. T. in Serotonin Receptor Subtypes: Basic and Clinical Aspects (ed. Peroutka, S. J.) 147–210 (Wiley-Liss, New York, 1991).
Tecott, L. H. & Julius, D. J. Curr. Opin. Neurobiol. 3, 310–315 (1993).
Julius, D., MacDermott, A. B., Axel, R. & Jessell, T. M. Science, 241, 558–564 (1988).
Molineaux, S., Jessell, T., Axel, R. & Julius, D. Proc. natn. Acad. Sci. U.S.A. 86, 6793–6797 (1989).
Hoffman, B. J. & Mezey, E. FEBS Lett. 247, 453–462 (1989).
Pompeiano, M., Palacios, J. M. & Mengod, G. Molec. Brain Res. 23, 163–178 (1994).
Yu, L. et al. Molec. Brain Res. 11, 143–149 (1991).
Milatovich, A. et al. Hum. molec. Genet. 1, 681–684 (1992).
Thomas, L., Power, B., Hudson, P., Schreiber, G. & Dziadek, M. Devl Biol. 128, 415–427 (1988).
Orloff, M. J., Williams, H. L. & Pfeiffer, C. C. Proc. Soc. exp. Biol. Med. 70, 254–257 (1949).
Blundell, J. E. Am. J. clin. Nutr. 55, 155–159S (1992).
Wurtman, J. et al. Neuropsychopharmacology 9, 201–210 (1993).
Samanin, R. et al. Naunyn-Schmiedebergs Arch. Pharmac. 308, 159–163 (1979).
Kennett, G. A. & Curzon, G. Br. J. Pharmac. 103, 2016–2020 (1991).
Kitchener, S. J. & Dourish, C. T. Psychopharmacology 113, 369–377 (1994).
Parkinson, W. L. & Weingarten, H. P. Am. J. Physiol. 259, R829–R835 (1990).
Himms-Hagen, J. Front. Neuroendocr. 12, 38–93 (1991).
Kilian, M. & Frey, H. H. Neuropharmacology 12, 681–692 (1973).
Jobe, P. C. Picchioni, A. L. & Chin, L. Life Sci. 13, 1–13 (1973).
Sparks, D. L. & Buckholtz, N. S. Pharmac. Biochem. Behav. 23, 753–757 (1985).
Dailey, J. W., Slater, K., Crable, D. J. & Jobe, P. C. Fedn Proc. 46, 2282 (1987).
Engel, J. Seizures and Epilepsy (Davis, Philadelphia, 1989).
Friedman, J. M. & Leibel, R. L. Cell 69, 217–220 (1992).
Flier, J. S. Cell 80, 15–18 (1995).
Mansour, S. L., Thomas, K. R. & Capecchi, M. R. Nature 336, 348–352 (1988).
Tecott, L., Maricq, A. & Julius, D. Proc. natn. Acad. Sci. U.S.A. 90, 1430–1434 (1993).
Brake, A. J., Wagenbach, M. J. & Julius, D. Nature 371, 519–523 (1994).
Strack, A. M., Bradbury, M. J. & Dallman, M. F. Am. J. Physiol. 268, R183–191 (1995).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Tecott, L., Sun, L., Akana, S. et al. Eating disorder and epilepsy in mice lacking 5-HT2C serotonin receptors. Nature 374, 542–546 (1995). https://doi.org/10.1038/374542a0
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1038/374542a0
This article is cited by
-
Serotonin 5-HT2C receptor knockout in mice attenuates fear responses in contextual or cued but not compound context-cue fear conditioning
Translational Psychiatry (2022)
-
The diverse role of the raphe 5-HTergic systems in epilepsy
Acta Pharmacologica Sinica (2022)
-
Cognitive genomics of learning delay and low level of social performance monitoring in macaque
Scientific Reports (2022)
-
Lorcaserin for Dravet Syndrome: A Potential Advance Over Fenfluramine?
CNS Drugs (2022)
-
The hypothalamus for whole-body physiology: from metabolism to aging
Protein & Cell (2022)
Comments
By submitting a comment you agree to abide by our Terms and Community Guidelines. If you find something abusive or that does not comply with our terms or guidelines please flag it as inappropriate.